Lupin arm recalls 5,720 skin treatment cream tubes in US

The affected lot has been manufactured at the company's Pithampur plant in Madhya Pradesh and marketed in the US market by Baltimore-based Lupin Pharmaceuticals Inc. The USFDA noted that the company is recalling the affected lot due to "Subpotent Drug: Low assay result observed during long-term stability testing". The company initiated the Class III nationwide (US) recall of the affected lot on January 23 this year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CBUtGy2
via IFTTT

Read More

CDSCO suspends manufacturing of eye drops linked to 55 adverse events in United States

According to the people aware of the matter, the US-based Food and Drug Administration has warned the consumers "not to purchase or use EzriCare Artificial Tears due to potential contamination", and the Union Health Ministry's CDSCO and Tamil Nadu's State Drug Controller have initiated a probe into the matter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8ZxiHo2
via IFTTT

Read More

Difficult to scale up expensive therapy beyond a point: Kiran Mazumdar-Shaw

CAR-T therapies, previously not available in India, have shown promising results for patients who have exhausted all other means of treatment in a range of blood cancers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RUd6we4
via IFTTT

Read More

300 kids died due to cough syrups made in India: WHO

"These consultations are continuing as we enhance our work to encourage the multiple stakeholders to prevent, detect and respond to more incidents. WHO is reviewing existing guidance with a view to making any enhancements in case this is required. The associations' and industry involvement support is considered key," the WHO spokesperson said in an email response to ET.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5jA2ECV
via IFTTT

Read More

Central, state teams on way to Global Pharma Healthcare plant after firm recalls eye drop linked to vision loss in US

The US Food and Drug Administration has said in a statement that the Chennai-based company is recalling all lots of Artificial Tears lubricant eye drops distributed by EzriCare, LLC and Delsam Pharma to the consumer level due to possible contamination. To date, there are 55 reports of adverse events including eye infections, permanent loss of vision and a death with a bloodstream infection, it added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VQChjDw
via IFTTT

Read More

Max Healthcare lines up Rs 400 cr to expand Mohali facility

The construction of the new building that will house 170 beds officially commenced today. On completion of the project by the end of the third quarter of 2024, the hospital bed capacity will go up to 400 beds from the existing 231, it added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gX4SLRF
via IFTTT

Read More

Indian drug firm recalls eye drop linked to vision loss in US

In a statement posted on its website, Global Pharma Healthcare said it is notifying the distributors of this product Aru Pharma Inc and Delsam Pharma, and is requesting that wholesalers, retailers and customers who have the recalled product should stop using it. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using these over-the-counter drug products, it said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sNLijQK
via IFTTT

Read More